RM-END / Endocrine and peptide-hormone analogs
Teriparatide
Also known as: PTH(1-34) · Parathyroid hormone 1-34
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Teriparatide is the biologically active 1-34 fragment of human parathyroid hormone. It must be distinguished from full-length PTH and from other PTH-receptor analogs.
Evidence position
FDA-labeled products and randomized human data support Grade A for the regulated presentation.
What the record does not establish
Those records do not authenticate an independently produced PTH fragment or establish its lot quality.
Sources
- 01Forteo prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. finished-product label and PTH(1-34) identity
- Does not show
- Does not establish quality of another peptide source
- 02PTH(1-34) fracture and bone-density randomized trialPubMed
- Shows
- Randomized human evidence for a defined teriparatide presentation
- Does not show
- Clinical evidence is not analytical testing
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Teriparatide
- CID
- 16133850
- Formula
- C181H291N55O51S2
- Mass
- 4118
PUBMED / FOUND RECORDS
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.Lancet (London, England) / 2015 Sep 19PMID 26144908 / DOI 10.1016/S0140-6736(15)61120-5
- Teriparatide. / 2012PMID 31644031
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA / 2025 JunPMID 40047881 / DOI 10.1007/s00198-025-07440-1
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.Archives of osteoporosis / 2024 Sep 23PMID 39312040 / DOI 10.1007/s11657-024-01447-7
- Teriparatide: a review.Clinical therapeutics / 2004 JunPMID 15262455 / DOI 10.1016/s0149-2918(04)90128-2
CLINICALTRIALS.GOV / FOUND RECORDS
- Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCTNOT_YET_RECRUITING / PHASE1, PHASE2 / University of CalgaryNCT06303284 / DIRECT intervention MATCH: Teriparatide
- The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKLWITHDRAWN / NA / Leland Graves III, MDNCT00347737 / DIRECT intervention MATCH: Teriparatide
- Teriparatide as a Chondroregenerative Therapy in OACOMPLETED / PHASE2 / Christopher RitchlinNCT03072147 / DIRECT intervention MATCH: Teriparatide
- OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal WomenCOMPLETED / PHASE4 / SanofiNCT00130403 / DIRECT title MATCH: Teriparatide
- Denosumab, Teriparatide or Both for the Treatment of Postmenopausal OsteoporosisCOMPLETED / PHASE2 / Massachusetts General HospitalNCT00926380 / DIRECT intervention MATCH: Teriparatide